The goal of the current study was to describe the distribution and characteristics of malignancyrelated deaths among human immunodeficiency virus (HIV)-infected patients with use of data obtained from a national survey conducted in France in 2005 and to compare with results obtained from a similar survey conducted in 2000.
lomavirus, and hepatitis B virus [HBV] infection) and to cellular immunodepression, as demonstrated by the use of immunosuppressive drugs, particularly during transplantation [2, 3] . The widespread use of combination antiretroviral therapies (cART) in industrialized countries since the middle of the 1990s has been associated with a dramatic decrease in the incidence of both mortality and AIDS-related events. However, the incidences of NHL and cervical cancer decreased in a lower proportion than did other opportunistic infections [4, 5] . Prolonged life expectancy was associated with a diversification of morbidity and causes of death to include cardiovascular events, hepatic complications, bacterial infections and non-AIDS-related cancers [6] [7] [8] [9] [10] [11] [12] . In a national survey conducted in France in 2000, we demonstrated that 12% of deaths were attributable non-AIDS-related cancers and that all cancers (i.e., AIDS-related and non-AIDS-related malignancies) accounted for 29% of the deaths [13] . The monitoring of epidemiologic trends would permit the defining of priorities with regard to prevention, early detection, and treatment of AIDS-related and non-AIDS-related malignancies. The objectives of the present study were to describe the distribution and characteristics of malignancy-related deaths among HIV-infected patients in France in 2005 and to assess changes that occurred from the study in 2000.
PATIENTS AND METHODS

Data collection.
All hospital wards and networks in France that were known to be involved in the treatment of HIV-infected patients were contacted, including wards that participated in the Mortalité 2000 survey. Apart from contacting a greater number of physicians than in 2000, the study design was similar to that of the previous survey [7] .
Physicians were asked to prospectively report and document deaths and provide an abstract of the cause of death for HIVinfected adults (aged у18 years) every 3 months in 2005. Each death was then documented using a standardized questionnaire that included all contributing causes of death, diseases present at time of death, and a global assessment of the underlying cause of death. One physician, who was a part of the coordinating team, oversaw the harmonization of data collection. Double reports were identified by matching the dates of birth and death. Hepatitis C virus (HCV) infection was defined as the presence of HCV antibodies or HCV RNA in serum; excessive alcohol consumption was defined as a daily alcohol intake greater than 50 grams and/or 5 glasses; and poor socioeconomic condition was defined as health insurance, no employment, no accommodation, income below 535i per month, and/or an illegal immigration status.
Determination of the underlying cause of death. Information contained in the questionnaire was used to determine the underlying cause of death according to the rules of the International Classification of Diseases, 10th revision. The underlying cause of death was defined as the disease or injury that initiated the sequence of morbid events that led to death [14] . The algorithm of determination was adapted to the specific concerns of HIV infection [7] and allowed the categorization of deaths as follows: AIDS-related causes were categorized according to the 1993 clinical classification [1]; deaths related to HCV/HBV infection, including hepatocarcinoma; cancers and other causes not related to AIDS or HCV/HBV infection; and adverse effects of antiretroviral treatment. Adverse effects of antiretroviral treatment was considered to be the underlying cause of death only when this was the explicit conclusion of the physician. Cancers were classified as AIDS related when active pathology at the time of death included one AIDS- 
RESULTS
A total of 1042 deaths were reported in 2005 (964 were reported in 2000) among ∼78,000 HIV-infected patients observed (i.e., patients with at least 1 contact with participating physicians during 2005) at the 340 wards participating in the survey. Documentation was available for 1013 decedents (97%); 76% were men, the median age was 46 years (median age in 2000, 41 years), the known duration of HIV infection was 12 years (duration in 2000, 8 years), 87% had received an antiretroviral treatment (86% in 2000), 47% had a plasma HIV-RNA level !500 copies/mL (33% in 2000), the median CD4 lymphocyte count was 161 cells/mm 3 (median count in 2000, 94 cells/mm 3 ), 55% of patients had a CD4 cell count !200 cells/mm 3 (68% in 2000) , and 12% of patients had a CD4 cell count 1500 cells/ mm 3 (9% in 2000) . Underlying causes of death. In the Mortalité 2005 survey, the most frequent underlying cause of death was an AIDSdefining illness in 375 cases (36% in 2005 vs. 47% in 2000), followed by non-AIDS/hepatitis-related cancer ( ; 17% n p 173 vs. 11%), liver-related cause ( ; 15% vs. 13%), cardion p 154 vascular disease ( ; 8% vs. 7%), suicide ( ; 5% vs. n p 88 n p 50 4%), and other infections ( ; 4% vs. 7%). n p 46 Among the 1013 cases with information provided, 344 malignancy-related causes of death (34% of deaths) were recorded; they were distributed as NHL ( ; 10% of the causes of n p 103 death), Kaposi sarcoma ( ; 2%), hepatitis-related hepan p 25 tocarcinoma ( ; 4%) and non-AIDS/hepatitis-related n p 37 cancers ( ; 17%) (table 1). The proportion or deaths n p 173 attributable to malignancies increased statistically significantly, compared with that in 2000 when malignancies accounted for 29% of the causes of death ( ) (table 2) . Adjusted for P p .02 age and sex, the proportion of deaths attributable to hepatocarcinoma or non-AIDS/hepatitis-related cancer increased statistically significantly from 2000 to 2005, with a greater diver- . Ninety-one percent of patients with death attributable to respiratory cancer had previously been treated with antiretrovirals, and 63% had plasma HIV-RNA levels !500 copies/mL. Ninety percent of these patients were smokers, and 34% had excessive alcohol consumption. Hepatocarcinoma was mainly associated with hepatitis C virus coinfection in 2005, whereas hepatocarcinoma etiology was better balanced between HBV and HCV coinfection in 2000. Patients who died of hepatocarcinoma had a median age of 49 years and were known to be infected with HIV for a median of 15 years. Ninety-five percent of these patients had previously been treated with antiretrovirals, 69% had HIV-RNA levels !500 copies/mL at time of death, and these patients had moderate immunosuppression (median CD4 count, 231 cells/mm 3 (16) 134 (13) Non-Hodgkin lymphoma 105 (11) 103 (10) Kaposi sarcoma 40 (4) 25 (3) Cervical cancer 4 (0.4) 6 (0.6) Hepatitis related All 17 (2) 37 (4) Hepatitis C virus 8 (0.9) 28 ( Non-AIDS/hepatitis related All 103 (11) 173 (17) Respiratory All 50 (5) 65 (6) Lung 44 (5) 53 (5) Nose and throat 6 (0. 
), connective and soft tissue ( ), penis ( ), and bladder n p 1 n p 1 n p 1 ( ). In the Mortalité 2005 survey, others included unknown origin n p 1 ( ); hepatocarcinoma ( ); ovary ( ); prostate ( ); uterus n p 15 n p 4 n p 2 n p 2 ( ); penis ( ); bladder ( ); head, face, and neck ( ); kidney n p 2 n p 2 n p 2 n p 1 ( ); intrahepatic bile duct ( ); and mandible ( ). n p 1 n p 1 n p 1 coma and cervical cancer remained similar between the 2000 and 2005 surveys.
DISCUSSION
In this large national prospective survey specifically designed to assess the primary causes of death among HIV-infected patients, we demonstrated that malignancies accounted for more than one-third of the causes of death in this population of patients. We also demonstrated that the proportion of deaths attributable to malignancies increased statistically significantly since 2000. The proportion of non-AIDS-related cancers also significantly increased from 2000 to 2005, although these patient populations had similar CD4 cell counts (median CD4 count, 218 cells/mm 3 in 2000 vs. 205 cells/mm 3 in 2005). These results are consistent with those of the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study, which demonstrated that immunosuppression, as reflected by the latest CD4 count, was strongly associated with the risk of death attributable to non-AIDS-defining malignancies; patients whose death was attributable to these malignancies in the D:A:D study had a median CD4 cell count of 211 cells/mm 3 at time of death [15] . The risk of non-AIDS-related cancer is greater among HIVinfected patients than in the general population [16, 17] . The increasing proportion of deaths attributable to non-AIDS-defining malignancies may be related first to the aging of this subpopulation (median age, 46 years in 2000 vs. 49 years in 2005), but it is also probably related to poor control of risk factors (e.g., tobacco use among patients with respiratory cancer and human papillomavirus infection among patients with anal cancer). The increasing proportion of respiratory malignancies emphasizes the need for a better implementation of active smoking cessation programs. In addition, the increased proportion of lethal digestive cancers (especially pancreatic cancer) and breast cancer (7 patients in 2005 vs. none in 2000) observed in this study should be emphasized.
The role of cART is still a matter of debate. Burgi et al. [18] demonstrated that cART appeared to be beneficial in protecting against the development of malignant disease, whereas conflicting results have been reported in the D:A:D study, especially with regard to Hodgkin lymphoma [15] . This issue should be specifically addressed in future studies to provide evidencebased recommendations for cART treatment in HIV-infected patients. The beneficial role of cART, in terms of cancer prevention, might be delayed for non-AIDS-defining causes of death, especially cancers. Because of this, after several years of cART, the mortality rate in a subgroup of HIV-infected persons with CD4 counts 1500 cells/mm 3 was demonstrated to reach a similar level to that of the general population [19] . From 2000 to 2005, the proportion of hepatitis-related hepatocarcinoma significantly increased, which confirming data reported in other series [20] . However, the proportion of HBV-related hepatocarcinoma remained stable, whereas a 3-fold increase was observed for HCV-related hepatocarcinoma. The widespread use of antiretroviral treatments (e.g., emtricitabine and tenofovir) that are effective against HBV might explain this discordant change over time. We also noticed an increased proportion of HCV-related hepatocarcinoma in the older population that was described in 2005, despite a better control of HIV infection (median CD4 count, 231 cells/mm 3 in 2005 vs. 157 cells/mm 3 in 2000) , suggesting that the control of HCV infection is insufficient among HIV-infected patients.
Despite the widespread use of cART and the improved management of long-term antiretroviral treatments, the proportion of AIDS-defining cancer, particularly NHL, did not decrease over time. NHL remained the most frequently observed AIDSdefining event leading to death. The incidence of NHL has decreased dramatically since the introduction of cART but to a lesser degree than the other opportunistic infections, and the incidence has remained stable since 1996 [21] . Moreover, the response rate and the survival rate remain poor (∼75%), particularly among patients with CD4 counts !100 cells/mm 3 , a history of previous opportunistic infections, and poor general status [22] . Because the risk of NHL clearly decreases with increases in CD4 count, the best way to prevent NHL could be to reach or maintain a high CD4 count [23] . However, other factors independent of immunosuppression (i.e., HIV and Epstein-Barr virus replication) may also have an impact on the risk of NHL [21] [22] [23] [24] .
In conclusion, this study demonstrated a stable proportion of AIDS-related cancer that led to death between 2000 and 2005. However, an increasing proportion of patients with death attributable to non-AIDS-related cancer was observed among HIV-infected patients; these cancers included lung cancer, nose and throat cancer, digestive and pancreas cancer, skin cancer, breast cancer, and anal cancer. Cancer prevention, screening, early diagnosis, and improved management and surveillance should be included in routine long-term follow-up of HIVinfected patients and could have some immediate impact on mortality. Moreover, because the median CD4 cell level was !250 cells/mm 3 in this population of HIV-infected patients, the therapeutic goal should be to maintain or to reach as high a CD4 count as possible, in addition to other usual prevention policy that is systematically implemented in this population, to prevent cancer-related deaths.
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